Advent Venture Partners is a London-based venture capital firm established in 1981, specializing in investments in early and mid-stage companies within the life sciences and technology sectors. The firm is recognized as one of Europe’s leading growth and venture capital investors, with a team of professionals who possess extensive scientific, medical, and operational expertise. Advent focuses on a select number of companies, fostering strong partnerships with entrepreneurs to build and develop valuable businesses. Their investment strategy encompasses various areas within life sciences, including new drug discovery, enabling technologies, and medical technology, while also covering sectors such as information technology and diagnostics. Notable past investments include companies like Algeta and Micromet, and their current portfolio features businesses such as Acutus and Biocartis.
Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.
Relief Cardiovascular
Series A in 2025
Relief Cardiovascular is a medical technology company focused on developing an innovative implantable device aimed at treating congestive heart failure. The company's smart implant is designed to monitor blood flow and alleviate congestion in the heart, which may lead to improved health outcomes for patients suffering from this condition. By providing a targeted treatment option, Relief Cardiovascular seeks to enhance the management of heart failure and improve the quality of life for affected individuals.
Epitopea
Seed Round in 2024
Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.
Moximed
Series D in 2024
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.
Artax Biopharma
Convertible Note in 2024
Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.
Argá Medtech
Series B in 2024
Argá Medtech specializes in the development of an innovative cardiac ablation system aimed at treating cardiac arrhythmias, particularly ventricular tachycardia. The company has created a proprietary coherent sine-burst electroporation system that enhances treatment effectiveness through increased power and depth. This advanced technology features an innovative catheter design that eliminates the need for exchanges, thereby improving flexibility and efficiency in clinical applications. As a result, Argá Medtech's solutions enable healthcare professionals to optimize therapeutic outcomes and streamline the treatment process for patients suffering from arrhythmias.
Curve Therapeutics
Series A in 2024
Curve Therapeutics Limited is a drug-discovery company based in London, United Kingdom, founded in 2019. The company focuses on developing technologies to target currently undruggable disease-modifying targets, with a primary emphasis on cancer. Curve has created an innovative screening platform that allows for the functional screening of genetically encoded Microcycle™ libraries against a variety of disease-associated targets in their native conformation within mammalian cells. This platform is designed to facilitate the discovery of first-in-class therapeutics, enabling the development of a pipeline of novel cancer drugs. By targeting challenging cancer interactions, including intracellular protein-protein and protein-gene interactions, Curve Therapeutics aims to deliver advanced treatments for complex cancer-related conditions.
Nalu Medical
Series E in 2024
Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.
PIC Therapeutics
Series A in 2022
PIC Therapeutics, Inc. is a biotechnology company dedicated to innovating cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and based in Boston, Massachusetts, the company focuses on developing therapeutics that target the "master switch" of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This precision-based approach has the potential to simultaneously address multiple oncogenic drivers, thereby improving patient outcomes and advancing a new generation of cancer treatments.
Tridek-One
Venture Round in 2022
Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.
Moximed
Series C in 2022
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.
MiroBio
Series B in 2022
MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.
Wondr Medical
Seed Round in 2022
Wondr Medical is a London-based company that operates a platform designed to connect health professionals globally. Established in 2016, the platform facilitates innovation and collaboration within the healthcare sector by enabling professionals to share ideas, stay informed, and discover medical events. It also assists users in job searches, creating a comprehensive network that enhances communication among medical teams. Through its services, Wondr Medical aims to accelerate discovery in the health industry.
Artax Biopharma
Venture Round in 2022
Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.
Epitopea
Seed Round in 2022
Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.
Nalu Medical
Venture Round in 2022
Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.
AviadoBio
Series A in 2021
AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.
NeRRe Therapeutics
Series B in 2021
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.
Aura Biosciences
Venture Round in 2021
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Amphista Therapeutics
Series B in 2021
Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.
Wiz
Series B in 2021
Wiz, Inc. is a cybersecurity company founded in 2020, with headquarters in Palo Alto, California, and an additional office in Tel Aviv, Israel. The company specializes in cloud security, providing enterprises with a platform that enables them to identify security issues within their public cloud infrastructure. Wiz's innovative solution offers a comprehensive, cloud-native visibility tool that analyzes the entire cloud environment, delivering a 360-degree view of security risks across various platforms, including clouds, containers, and workloads. The platform utilizes actionable, graph-based analysis to facilitate in-depth risk assessment and root cause analysis without the need for agents, allowing organizations to enhance their security posture effectively.
Highlight Therapeutics
Venture Round in 2021
Highlight Therapeutics is a private, clinical-stage company focused on developing RNA-based immuno-oncology therapies aimed at treating cancer. The company's innovative therapies mimic the effects of viral infections to enhance the therapeutic impact of existing drugs. This approach allows medical professionals to promote quicker tumor recovery in patients, thereby unlocking the potential of immuno-oncology in cancer treatment.
Rappta Therapeutics
Series A in 2020
Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), a vital enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage of creating a first-in-class series of molecules aimed at reactivating this key tumor suppressor. The firm employs proprietary development tools to facilitate rational drug design, aiming to provide therapeutic solutions for various cancer types and select non-oncology conditions.
F2G
Venture Round in 2020
F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.
Zikani Therapeutics
Series A in 2020
Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.
PIC Therapeutics
Seed Round in 2020
PIC Therapeutics, Inc. is a biotechnology company dedicated to innovating cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and based in Boston, Massachusetts, the company focuses on developing therapeutics that target the "master switch" of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This precision-based approach has the potential to simultaneously address multiple oncogenic drivers, thereby improving patient outcomes and advancing a new generation of cancer treatments.
Amphista Therapeutics
Series A in 2020
Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.
AviadoBio
Seed Round in 2020
AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.
MiroBio
Series A in 2019
MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.
Acutus Medical
Series D in 2019
Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.
Tridek-One
Venture Round in 2019
Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.
KaNDy Therapeutics
Series C in 2018
KaNDy Therapeutics is a biotechnology company based in Stevenage, United Kingdom, focused on developing non-hormonal treatments for various menopausal symptoms, including hot flashes and nighttime awakenings. Established in 2017, the company is known for its drug NT-814, which addresses moderate to severe post-menopausal vasomotor symptoms. By providing non-hormonal therapies, KaNDy Therapeutics aims to alleviate the debilitating effects of hormone-related conditions in women. As a subsidiary of Bayer Aktiengesellschaft, the company leverages its research and development capabilities to enhance the quality of life for patients experiencing these common symptoms.
Zikani Therapeutics
Venture Round in 2018
Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.
Aura Biosciences
Series C in 2017
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Vestagen
Venture Round in 2017
Vestagen Technical Textiles, founded in 2009 and based in Orlando, Florida, specializes in developing, manufacturing, and marketing innovative textile products and technologies. The company holds exclusive North American rights to patented Swiss technologies for medical textiles, allowing for versatile applications ranging from medical uniforms to athletic apparel. Vestagen's primary focus is on addressing critical needs within the healthcare industry, particularly through its proprietary VESTEX Active Barrier fabric. This advanced material is designed to protect healthcare workers and patients by minimizing the risks associated with fluid exposure and reducing the retention of harmful microorganisms on clothing.
Iterum Therapeutics
Series B in 2017
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing anti-infective therapies to address multi-drug resistant pathogens. Headquartered in Dublin, Ireland, the company is advancing its lead product, sulopenem, a novel penem compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem is being evaluated for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum aims to provide effective solutions to combat antibiotic resistance, particularly against a range of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Founded in 2015, Iterum Therapeutics seeks to improve the lives of patients affected by serious and life-threatening infections globally.
Axonics Modulation Technologies
Series C in 2017
Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.
Moximed
Series C in 2017
Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.
Arrakis Therapeutics
Series A in 2017
Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.
NeRRe Therapeutics
Series B in 2017
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.
Aleta Biotherapeutics
Venture Round in 2016
Aleta Biotherapeutics is an immuno-oncology company established in 2015 and headquartered in Natick, Massachusetts. The company specializes in the development of cellular therapeutics aimed at addressing a wide range of cancer indications, particularly focusing on challenging and intractable solid tumors. By transforming cellular therapeutics, Aleta Biotherapeutics enables healthcare professionals to target various tumor types more effectively, thus enhancing treatment options for patients facing difficult cancer cases.
F2G
Venture Round in 2016
F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.
Acutus Medical
Series C in 2016
Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.
Capella BioScience
Series A in 2016
Capella BioScience specializes in the discovery and development of monoclonal antibodies (mAbs) aimed at creating therapeutics for oncology, autoimmune diseases, and other medical conditions. The company employs proprietary technologies to innovate in the development and commercialization of mAbs-based medicines. In addition to its independent efforts, Capella collaborates with biotechnology firms and academic institutions to advance its research and expand the reach of its therapeutic solutions.
Vestagen
Venture Round in 2016
Vestagen Technical Textiles, founded in 2009 and based in Orlando, Florida, specializes in developing, manufacturing, and marketing innovative textile products and technologies. The company holds exclusive North American rights to patented Swiss technologies for medical textiles, allowing for versatile applications ranging from medical uniforms to athletic apparel. Vestagen's primary focus is on addressing critical needs within the healthcare industry, particularly through its proprietary VESTEX Active Barrier fabric. This advanced material is designed to protect healthcare workers and patients by minimizing the risks associated with fluid exposure and reducing the retention of harmful microorganisms on clothing.
Axonics Modulation Technologies
Series B in 2015
Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.
Artax Biopharma
Series B in 2015
Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Founded in 2013 and based in Cambridge, Massachusetts, the company specializes in small-molecule drugs that act as immunomodulators. Its lead compound, AX-024, specifically targets Nck, disrupting the interaction that activates T-cells, thereby preventing harmful responses against antigens while maintaining the immune system's ability to combat infections. Artax Biopharma's research encompasses a range of conditions, including asthma, rheumatoid arthritis, psoriasis, graft versus host disease, and multiple sclerosis. By aiming to treat both symptoms and underlying disease mechanisms, the company's therapies are designed to minimize side effects associated with traditional treatments.
Vestagen
Convertible Note in 2015
Vestagen Technical Textiles, founded in 2009 and based in Orlando, Florida, specializes in developing, manufacturing, and marketing innovative textile products and technologies. The company holds exclusive North American rights to patented Swiss technologies for medical textiles, allowing for versatile applications ranging from medical uniforms to athletic apparel. Vestagen's primary focus is on addressing critical needs within the healthcare industry, particularly through its proprietary VESTEX Active Barrier fabric. This advanced material is designed to protect healthcare workers and patients by minimizing the risks associated with fluid exposure and reducing the retention of harmful microorganisms on clothing.
Nalu Medical
Venture Round in 2015
Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.
Aura Biosciences
Series B in 2015
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
WorldStores
Series D in 2015
WorldStores Limited is a prominent online retailer in the United Kingdom, specializing in a wide range of home and garden products. Established in 2008, the company offers an extensive selection of items, including bedroom furniture, living room furnishings, kitchenware, outdoor products, and DIY supplies. Its catalog features products for various spaces, accommodating various customer needs, from garden furniture and outdoor play items to pet supplies and home décor. WorldStores is recognized for its competitive pricing, exceptional customer service, and flexible delivery options, contributing to its status as a leading e-commerce brand. The company is headquartered in Twickenham, United Kingdom, and operates as a subsidiary of Globe Online Limited.
Calcico Therapeutics
Venture Round in 2015
Calcico Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing novel small molecule drugs for autoimmune and inflammatory disorders. Founded in 2012, the company specializes in creating selective inhibitors of calcium-release activated channels (CRAC), targeting conditions with established links to CRAC dysfunction. Calcico has developed proprietary systems for CRAC channel screening and molecule characterization, placing it in a unique position to achieve effective and selective CRAC channel inhibition, a challenge that has been difficult for larger pharmaceutical companies to address. Through its innovative approach, Calcico aims to provide new treatment options for various inflammatory and autoimmune diseases, including atopic dermatitis.
GMP Orphan
Series A in 2015
gmp-orphan (GMPO), it is their mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Their experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission.
Farfetch
Series D in 2014
Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.
Versartis
Series E in 2014
Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.
Vestagen
Series A in 2013
Vestagen Technical Textiles, founded in 2009 and based in Orlando, Florida, specializes in developing, manufacturing, and marketing innovative textile products and technologies. The company holds exclusive North American rights to patented Swiss technologies for medical textiles, allowing for versatile applications ranging from medical uniforms to athletic apparel. Vestagen's primary focus is on addressing critical needs within the healthcare industry, particularly through its proprietary VESTEX Active Barrier fabric. This advanced material is designed to protect healthcare workers and patients by minimizing the risks associated with fluid exposure and reducing the retention of harmful microorganisms on clothing.
Versartis
Series D in 2013
Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.
Vestagen
Venture Round in 2013
Vestagen Technical Textiles, founded in 2009 and based in Orlando, Florida, specializes in developing, manufacturing, and marketing innovative textile products and technologies. The company holds exclusive North American rights to patented Swiss technologies for medical textiles, allowing for versatile applications ranging from medical uniforms to athletic apparel. Vestagen's primary focus is on addressing critical needs within the healthcare industry, particularly through its proprietary VESTEX Active Barrier fabric. This advanced material is designed to protect healthcare workers and patients by minimizing the risks associated with fluid exposure and reducing the retention of harmful microorganisms on clothing.
Acutus Medical
Series B in 2013
Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.
Versartis
Series C in 2013
Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.
WorldStores
Series C in 2013
WorldStores Limited is a prominent online retailer in the United Kingdom, specializing in a wide range of home and garden products. Established in 2008, the company offers an extensive selection of items, including bedroom furniture, living room furnishings, kitchenware, outdoor products, and DIY supplies. Its catalog features products for various spaces, accommodating various customer needs, from garden furniture and outdoor play items to pet supplies and home décor. WorldStores is recognized for its competitive pricing, exceptional customer service, and flexible delivery options, contributing to its status as a leading e-commerce brand. The company is headquartered in Twickenham, United Kingdom, and operates as a subsidiary of Globe Online Limited.
Farfetch
Series C in 2013
Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.
Versartis
Series C in 2013
Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.
Avidex
Venture Round in 2012
Avidex is a full-service audiovisual firm specializing in the design, integration, and support of audiovisual solutions for commercial and healthcare clients across the United States. The company provides a comprehensive range of services, including strategic planning, system design, deployment, training, and managed support, aimed at enhancing collaborative experiences. Avidex partners with architects, contractors, consultants, and educators to develop various environments such as boardrooms, videoconference rooms, auditoriums, and training facilities. With a workforce of over 130 employees, Avidex boasts extensive expertise in implementing audiovisual and multimedia technologies. The firm has successfully completed international projects across more than a dozen countries and has executed jobs in over 26 states, establishing itself as a reliable single source for all audiovisual needs.
NeRRe Therapeutics
Series A in 2012
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.
CardiAQ Valve Technologies
Series B in 2012
CardiAQ Valve Technologies is a privately held company specializing in advanced solutions for heart valve replacement, with a primary focus on transcatheter mitral valve implantation (TMVI). The company has developed a system that allows physicians to implant a mitral valve within a beating heart, thereby eliminating the need for open-heart surgery. This innovative approach aims to enhance patient outcomes and simplify the procedure for both patients and healthcare providers.
F2G
Venture Round in 2012
F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.
Ubiquisys
Venture Round in 2012
Ubiquisys is a mobile communications company that specializes in designing and developing communications devices tailored for both mobile operators and consumers. The company is known for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband networks to deliver 3G coverage, thereby enhancing mobile connectivity in these environments. In addition to its femtocell technology, Ubiquisys also provides solutions aimed at the wireless-wireline convergence technology market, contributing to the integration of diverse communication services.
CN Creative
Series A in 2012
CN Creative, headquartered in the Bioscience Incubator at Manchester University in the UK, focuses on addressing global challenges linked to smoking and smoking-related illnesses through innovative and sustainable solutions. The company has developed a range of products and services aimed at smoking cessation and harm reduction. Its offerings include QuitDirect, an NHS-accredited provider of smoking cessation services, the Intellicig® electronic cigarette, and ECOpure, a line of proprietary high-purity nicotine preparations. Additionally, CN Creative offers NRT Direct, which supplies traditional nicotine replacement therapy products and support services for both public and private smoking cessation programs. Currently, the Nicadex(TM) electronic inhaler, a nicotine replacement therapy product, is in clinical development for use in medically supervised smoking cessation initiatives.
Farfetch
Series B in 2012
Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.
Acutus Medical
Series A in 2011
Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.
WorldStores
Debt Financing in 2011
WorldStores Limited is a prominent online retailer in the United Kingdom, specializing in a wide range of home and garden products. Established in 2008, the company offers an extensive selection of items, including bedroom furniture, living room furnishings, kitchenware, outdoor products, and DIY supplies. Its catalog features products for various spaces, accommodating various customer needs, from garden furniture and outdoor play items to pet supplies and home décor. WorldStores is recognized for its competitive pricing, exceptional customer service, and flexible delivery options, contributing to its status as a leading e-commerce brand. The company is headquartered in Twickenham, United Kingdom, and operates as a subsidiary of Globe Online Limited.
Prexa Pharmaceuticals
Series B in 2011
Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.
Ampla Pharmaceuticals
Venture Round in 2011
Ampla Pharmaceuticals designs and develops biopharmaceutical drugs. The company was incorporated in 2006 and is based in La Jolla, California.
Vitrue
Series C in 2011
Vitrue is a provider of social media marketing solutions designed for marketers, agencies, and publishers. The company offers a comprehensive cloud-based platform that enables brands to effectively manage their social marketing efforts across various networks, including Facebook, Twitter, Google+, and YouTube. Vitrue's award-winning Social Relationship Management (SRM) platform supports over one billion social connections globally, managing more than 4,500 social accounts in over 100 countries. Its services include promotional programs, branded community development, and syndicated brand applications, along with centralized data and member management, strategic consultation, and event marketing integration. Vitrue aims to maximize the marketing potential of social media for its clients while ensuring security and scalability in its operations.
Versartis
Series B in 2011
Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.
Conatus Pharmaceuticals
Series B in 2011
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Cellnovo
Series B in 2011
CellNovo is a medical device company focused on diabetes management. The company develops and markets a comprehensive system that includes a cordless micro-pump, an integrated monitoring device, and a cellular handset with a touch screen and embedded blood glucose meter. This innovative system facilitates the automatic transmission of data, allowing for real-time monitoring of patients' conditions through mobile connectivity. By creating an interconnected diabetes management solution, CellNovo aims to enhance the quality of care for individuals living with diabetes.
Pathwork Diagnostics
Series C in 2010
Pathwork Diagnostics, located in Redwood City, California, specializes in developing and delivering innovative molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers, by utilizing genomic information from the tumors. Pathwork Diagnostics offers laboratory services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen tissues, providing essential support in cancer diagnosis and treatment planning.
Ubiquisys
Venture Round in 2010
Ubiquisys is a mobile communications company that specializes in designing and developing communications devices tailored for both mobile operators and consumers. The company is known for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband networks to deliver 3G coverage, thereby enhancing mobile connectivity in these environments. In addition to its femtocell technology, Ubiquisys also provides solutions aimed at the wireless-wireline convergence technology market, contributing to the integration of diverse communication services.
AmberFin
Venture Round in 2010
AmberFin is a provider of content-based software services tailored for media and entertainment companies. The company focuses on helping content owners maximize the value of their TV, film, and video assets throughout the entire lifecycle, from capture to distribution. By utilizing its Emmy-award winning technology, AmberFin iCR, the company transforms both new and archived content into formats that meet customer demands while enhancing quality and reducing file sizes. This open standards platform is designed to be future-proof, enabling seamless delivery across various platforms, including the Internet, video on demand, television, and mobile devices. Through its solutions, AmberFin aims to increase revenue, lower costs, save time, and eliminate incompatibility issues for its clients.
OpenCloud
Venture Round in 2010
OpenCloud Limited, founded in 2000 and based in Cambridge, United Kingdom, specializes in providing service differentiation and network solutions for wireline and mobile operators, as well as mobile virtual network operators (MVNOs). The company offers a range of products, including the Rhino TAS, a telecom application server that supports various network technologies such as SS7 and LTE IMS. OpenCloud's solutions include service interaction and broking capabilities through Rhino SIS, multimedia telephony control with Rhino Sentinel VoLTE, and consumer-oriented applications like Rhino Sentinel Express. Additionally, the company provides an online charging interface and tools for developers to customize applications. With a focus on enhancing the telecommunications landscape, OpenCloud aims to enable real-time communications and streamline service delivery across diverse networks. Its clientele spans multinational groups and operators globally, with offices in various countries including New Zealand, Spain, Singapore, Indonesia, and Brazil. The company operates as a subsidiary of Metaswitch Networks Ltd.
Ubiquisys
Venture Round in 2010
Ubiquisys is a mobile communications company that specializes in designing and developing communications devices tailored for both mobile operators and consumers. The company is known for its ZoneGate femtocell system, a compact plug-and-play device that connects to home or office broadband networks to deliver 3G coverage, thereby enhancing mobile connectivity in these environments. In addition to its femtocell technology, Ubiquisys also provides solutions aimed at the wireless-wireline convergence technology market, contributing to the integration of diverse communication services.
Farfetch
Series A in 2010
Farfetch is an online platform established in 2008 that connects buyers and sellers in the luxury fashion sector. It collaborates with over 1,000 independent boutiques and luxury brands, offering a diverse range of products, including clothing, accessories, and footwear. The company operates a comprehensive e-commerce website that enables these retailers to showcase their inventories to nearly a million active customers. Farfetch's technology infrastructure is designed to facilitate the luxury fashion ecosystem, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. The platform also includes the Browns stores and the New Guard Group, enhancing its retail capabilities. Farfetch generates revenue by charging a commission on sales made through its marketplace, typically exceeding 30%.
Avila Therapeutics
Venture Round in 2010
Avila Therapeutics is focused on designing and developing covalent drugs aimed at treating viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule that acts as a protease inhibitor for hepatitis C virus. Founded in 2006 and based in Waltham, Massachusetts, Avila Therapeutics operates as a subsidiary of Celgene Corporation, following its acquisition in 2012. The company has also established a strategic alliance with Sanofi-Aventis to enhance its research and development efforts.
Biocartis
Series B in 2010
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.
Oxagen
Series C in 2009
Oxagen Limited is a biopharmaceutical company focused on developing and commercializing anti-inflammatory medications for asthma and other chronic allergic conditions. The company specializes in small molecule drugs, including OC000459, an oral CRTH2 antagonist aimed at treating eosinophilic asthma and allergic rhinoconjunctivitis. Oxagen's drug development targets the CRTH2 receptor, which plays a critical role in the initiation and maintenance of allergic responses. In addition to asthma, their pipeline includes treatments for autoimmune diseases, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Founded in 1996 and based in London, Oxagen serves customers in the United Kingdom, Russia, and other countries in the Commonwealth of Independent States.
Dailymotion
Series C in 2009
Dailymotion is a video-sharing platform launched in 2005 that focuses on providing a diverse range of content, including news, sports, music, entertainment, comedy skits, political debates, and gaming live-streams. With a global audience of 300 million users, Dailymotion emphasizes premium content sourced from trusted publishers, having revamped its user experience in 2017. The platform collaborates with significant global content partners such as Universal Music Group, BBC News, and VICE, among others. It features a sophisticated video player that ensures high-quality viewing experiences across over 30,000 channels, allowing publishers to monetize their video content effectively. Dailymotion facilitates an average of 600,000 uploads per month, connecting video-makers with audiences while supporting contextual advertising. The company is owned by Vivendi, a multinational media corporation based in Paris.
The Fizzback Group
Series B in 2009
The Fizzback Group, founded in 2004, specializes in customer engagement solutions that allow businesses to effectively capture and respond to customer feedback in real-time. Utilizing a unique artificial intelligence engine, their Fizzback solution automatically analyzes feedback gathered at the moment of experience, which helps companies understand and act on customer insights. By facilitating relevant responses and prompting company actions, Fizzback not only enhances customer relationships but also drives economic benefits through increased customer lifetime value and improved word-of-mouth referrals. The company's innovative approach empowers businesses to truly listen to their customers and leverage their feedback for better decision-making.
Biocartis
Series A in 2009
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.
Foundry
Acquisition in 2009
With a 20-year heritage and a portfolio of award-winning products, Foundry advances the art and technology of visual experience in partnership with creative leaders around the globe. Our products are used to create breathtaking visual effects sequences on a wide range of feature films, video-on-demand, television and commercials.
BridgeCo
Venture Round in 2009
BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.
Qype
Series A in 2008
Qype is a social network focused on user-generated reviews of businesses and locations, founded in 2005 by German entrepreneur Stephan Uhrenbacher. It features a comprehensive database that allows users to browse and discover highly rated places across Europe and beyond, covering more than 160,000 cities and towns in nine languages. Users can contribute by adding new locations, writing reviews, and sharing photos and videos. The platform also facilitates community engagement through message boards and groups. Qype is accessible via both its website and a mobile application, enabling users to find top-rated establishments near their current location.
OpenCloud
Series B in 2008
OpenCloud Limited, founded in 2000 and based in Cambridge, United Kingdom, specializes in providing service differentiation and network solutions for wireline and mobile operators, as well as mobile virtual network operators (MVNOs). The company offers a range of products, including the Rhino TAS, a telecom application server that supports various network technologies such as SS7 and LTE IMS. OpenCloud's solutions include service interaction and broking capabilities through Rhino SIS, multimedia telephony control with Rhino Sentinel VoLTE, and consumer-oriented applications like Rhino Sentinel Express. Additionally, the company provides an online charging interface and tools for developers to customize applications. With a focus on enhancing the telecommunications landscape, OpenCloud aims to enable real-time communications and streamline service delivery across diverse networks. Its clientele spans multinational groups and operators globally, with offices in various countries including New Zealand, Spain, Singapore, Indonesia, and Brazil. The company operates as a subsidiary of Metaswitch Networks Ltd.
EUSA Pharma
Venture Round in 2008
EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.
Orecon
Series A in 2008
Orecon Ltd. is a company based in Bodmin, United Kingdom, that specializes in the development of wave energy devices. Founded in 2002, Orecon focuses on harnessing the power of ocean waves to generate sustainable and affordable electricity. The company offers innovative technologies, including oscillating water column systems and multi resonant chamber devices, designed for effective wave energy conversion. Their multi resonant chamber technology is engineered to be robust and reliable, utilizing high-quality components to maximize energy capture while minimizing environmental impact. Orecon is committed to respecting the oceans while unlocking their potential as a renewable energy source.
Wisair
Series D in 2008
Wisair is a fabless semiconductor company providing single-chip based Ultra Wideband (UWB) and Wireless USB solutions for personal computing, consumer electronics, and mobile devices.
Moveme.com
Venture Round in 2008
Moveme.com is an online marketplace based in the U.K. that offers free, instant quotes for various moving-related services. The platform connects users with local moving-service providers, allowing them to easily compare options for moving and removal services. In addition to moving solutions, Moveme.com also facilitates access to home insurance, tradespeople, mortgage services, as well as television and broadband providers, and energy performance certificates. This comprehensive approach aims to streamline the moving process by providing essential services in one convenient web portal.
Cellnovo
Series A in 2008
CellNovo is a medical device company focused on diabetes management. The company develops and markets a comprehensive system that includes a cordless micro-pump, an integrated monitoring device, and a cellular handset with a touch screen and embedded blood glucose meter. This innovative system facilitates the automatic transmission of data, allowing for real-time monitoring of patients' conditions through mobile connectivity. By creating an interconnected diabetes management solution, CellNovo aims to enhance the quality of care for individuals living with diabetes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.